TW202135804A - 治療與s1p1受體相關之病況的方法 - Google Patents

治療與s1p1受體相關之病況的方法 Download PDF

Info

Publication number
TW202135804A
TW202135804A TW110100496A TW110100496A TW202135804A TW 202135804 A TW202135804 A TW 202135804A TW 110100496 A TW110100496 A TW 110100496A TW 110100496 A TW110100496 A TW 110100496A TW 202135804 A TW202135804 A TW 202135804A
Authority
TW
Taiwan
Prior art keywords
compound
individual
pharmaceutically acceptable
acceptable salt
salt
Prior art date
Application number
TW110100496A
Other languages
English (en)
Chinese (zh)
Inventor
凱薩琳 Ｍ 克拉絲比
葛普瑞 雅盧瓦利亞
安卓 克里斯多福 衛斯理 司福瑞奇
Original Assignee
美商艾尼納製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾尼納製藥公司 filed Critical 美商艾尼納製藥公司
Publication of TW202135804A publication Critical patent/TW202135804A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Steering-Linkage Mechanisms And Four-Wheel Steering (AREA)
TW110100496A 2020-01-06 2021-01-06 治療與s1p1受體相關之病況的方法 TW202135804A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062957535P 2020-01-06 2020-01-06
US62/957,535 2020-01-06

Publications (1)

Publication Number Publication Date
TW202135804A true TW202135804A (zh) 2021-10-01

Family

ID=76788331

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110100496A TW202135804A (zh) 2020-01-06 2021-01-06 治療與s1p1受體相關之病況的方法

Country Status (12)

Country Link
US (1) US20230338336A1 (https=)
EP (1) EP4087562A4 (https=)
JP (1) JP2023509698A (https=)
KR (1) KR20220124209A (https=)
CN (1) CN115066242A (https=)
AU (1) AU2021205465A1 (https=)
BR (1) BR112022012846A2 (https=)
CA (1) CA3166828A1 (https=)
IL (1) IL294071A (https=)
MX (1) MX2022008342A (https=)
TW (1) TW202135804A (https=)
WO (1) WO2021142030A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4404930A1 (en) * 2021-09-23 2024-07-31 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
KR20240134360A (ko) * 2022-01-13 2024-09-09 아레나 파마슈티칼스, 인크. 호르몬 치료와 조합되어 s1p1 수용체-연관된 장애를 치료하는 데 사용하기 위한 에트라시모드
CN118234492A (zh) * 2022-10-21 2024-06-21 次代生物科学株式会社 具有针对s1pr1和s1pr4的功能性抑制剂作用的用于预防或治疗圆形脱发症的药物组合物
KR102541577B1 (ko) * 2022-10-21 2023-06-13 주식회사 넥스트젠바이오사이언스 S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061567A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
US8580841B2 (en) * 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
MX2012005560A (es) * 2009-11-13 2012-10-05 Receptos Inc Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
ES2665461T3 (es) * 2009-11-13 2018-04-25 Celgene International Ii Sàrl Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
PH12012500940B1 (en) * 2009-11-13 2018-09-26 Receptos Llc Selective heterocyclic sphingosine 1 phosphate receptor modulators
US9198911B2 (en) * 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
MX2019009841A (es) * 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.

Also Published As

Publication number Publication date
KR20220124209A (ko) 2022-09-13
CN115066242A (zh) 2022-09-16
CA3166828A1 (en) 2021-07-15
US20230338336A1 (en) 2023-10-26
MX2022008342A (es) 2022-08-04
EP4087562A1 (en) 2022-11-16
JP2023509698A (ja) 2023-03-09
EP4087562A4 (en) 2024-01-10
AU2021205465A1 (en) 2022-07-14
IL294071A (en) 2022-08-01
WO2021142030A1 (en) 2021-07-15
BR112022012846A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
TW202135804A (zh) 治療與s1p1受體相關之病況的方法
JP5264739B2 (ja) ポリグルタミン伸長関連疾患を治療するための塩素グアナベンズ誘導体の使用
US20250295674A1 (en) Neuroactive steroids for treatment of cns-related disorders
JP2022516662A (ja) Ｓ１ｐ１受容体に関連する状態を治療する方法
WO2019186171A1 (en) Treatment of sarcopenic diseases
EP4395779A1 (en) Lou064 for treating multiple sclerosis
EP3983016A1 (en) Methods of treating cancer by targeting cold tumors
JP2023502355A (ja) Ｓ１ｐ１受容体に関連する状態を処置する方法
Wernicke et al. Antidepressants: duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP)
EP3334426A2 (en) Mdm2 inhibitors for treating uveal melanoma
HK40080125A (en) Methods of treating conditions related to the s1p1 receptor
EP3941465B1 (en) Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
TW202114656A (zh) 治療與s1p1 受體相關之病況的方法
Millar et al. Pos0020 efficacy and safety of secukinumab in patients with rotator cuff tendinopathy: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Wernicke et al. Antidepressants: The safety of duloxetine in the long-term treatment of diabetic neuropathic pain
KR102585038B1 (ko) 렙틴 수용체 길항제 펩타이드를 유효성분으로 함유하는 유방암 치료용 약학적 조성물
US20240415798A1 (en) Compositions and methods for treating mucositis
US20130261165A1 (en) Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death
Khan et al. AB1152 Musculoskeletal manifestation of diabetes mellitus is highly prevalent and is associated with poor diabetic control
HK40110203A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
WO2023212812A1 (en) Method and use of psilocybin in the prevention and treatment of stroke
Guerrero et al. AB1151 Polymyalgia rheumatica. new therapeutic strategy based on low dose of metrotexate plus local infiltration with corticosteroids
HK40085111A (en) Dosage regimen for the treatment of cancer
Paul et al. AB0427 Comparative safety of abatacept vs tofacitinib in adults with moderate-to-severe ra: a systematic literature review and network meta-analysis
EA052711B1 (ru) Лечение рака